Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
February 05, 2024 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing 12 week results from the Company’s Phase 2 clinical trial of...
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
November 27, 2023 16:15 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the 6th Annual Evercore ISI...
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
November 07, 2023 23:15 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 7,425,000...
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
November 07, 2023 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market...
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
November 06, 2023 06:30 ET
|
Celldex Therapeutics, Inc.
-Barzolvolimab met primary endpoint with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups--Mean change from baseline to week 12...
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
November 05, 2023 15:00 ET
|
Celldex Therapeutics, Inc.
- Response observed as early as week 1 and durable for up to 16 weeks -- Data support important role for mast cells in the pathogenesis of PN and potentially other chronic itch indications -- Phase 2...
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 02, 2023 16:01 ET
|
Celldex Therapeutics, Inc.
- Phase 2 CSU enrollment complete; topline data by YE 2023 -- Phase 1b PN data accepted at World Congress on Itch - HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc....
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
September 26, 2023 07:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo...
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
September 25, 2023 08:31 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Cantor Global Healthcare...
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023 16:01 ET
|
Celldex Therapeutics, Inc.
- Phase 2 CSU enrollment completed; topline data by YE 2023 - - Phase 1b PN data in Q4 2023 -- First patient dosed in Phase 2 EoE study - HAMPTON, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Celldex...